Results 101 to 110 of about 59,740 (225)

Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay

Movement Disorders, EarlyView.
Abstract Background The cerebrospinal fluid alpha‐synuclein seed amplification assay (CSFasynSAA) detects alpha‐synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined.
Sarah M. Brooker, Jacopo Pasquini, Seung Ho Choi, David‐Erick Lafontant, Seyed‐Mohammad Fereshtehnejad, Yashar Zeighami, Piergiorgio Grillo, Giulietta M. Riboldi, Houman Azizi, Roqaie Moqadam, Un Jung Kang, Kelly N.H. Nudelman, Andrew Siderowf, Caroline M. Tanner, Thomas F. Tropea, Tatiana Foroud, Lana M. Chahine, Brit Mollenhauer, Kalpana M. Merchant, Douglas Galasko, Christopher S. Coffey, Roseanne D. Dobkin, Ethan G. Brown, Roy N. Alcalay, Daniel Weintraub, Kenneth Marek, Tanya Simuni, Paulina Gonzalez‐Latapi, Nicola Pavese, Kathleen L. Poston, the Parkinson's Progression Markers Initiative   +30 more
wiley   +1 more source

LEWY BODY VARIANT OF ALZHEIMER DISEASE

Zdravniški Vestnik, 2003
Background. Clinicopathological studies indicate that Alzheimer’s disease (AD) is the most common neurodegenerative cause of dementia, the other frequent causes are AD combined with diffuse Lewy bodies and dementia with Lewy bodies (DLB) by itself.
Jera Jeruc, Aleš Kogoj, Marko Pišljar, Mara Popović   +3 more
doaj  

Delphi consensus guidelines for the use of striatal dopaminergic imaging and cardiac metaiodobenzylguanidine (MIBG) scintigraphy for the diagnosis of dementia and mild cognitive impairment with Lewy bodies

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION The aim of this Delphi process was to develop consensus guidelines to support the effective use of striatal dopaminergic imaging and cardiac metaiodobenzylguanidine (MIBG) scintigraphy in the diagnosis of dementia with Lewy bodies and mild ...
Paul C. Donaghy, Gemma Greenfinch, George Petrides, Joseph Kane, Hein J. Verberne, John‐Paul Taylor, John T. O'Brien, Alan J. Thomas, DLB Indicative Imaging Biomarker Study Group   +8 more
doaj   +1 more source

Lewy sjúkdómur [PDF]

, 2008
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/OpenFriederich (Fritz) Heinrich Lewy var gyðingur, fæddur í Berlín árið 1885 (1).
Jón Snædal
core  

Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. [PDF]

, 2009
Amyloid imaging represents a major advance in neuroscience, enabling the detection and quantification of pathologic protein aggregations in the brain. In this review we survey current amyloid imaging techniques, focusing on positron emission tomography ...
Jagust, WJ, Rabinovici, GD
core   +2 more sources

Early Autonomic Burden in Prodromal Parkinson's Disease Predicts Cognitive Impairment

Movement Disorders, EarlyView.
Abstract Background Autonomic dysfunction is a known contributor to cognitive impairment in Parkinson's disease (PD), but its impact during prodromal stage is unknown. Objective The aim was to determine whether early autonomic burden predicts incident cognitive impairment in prodromal PD.
A. Enrique Martinez‐Nunez, Kelly A. Mills, Joseph Seemiller, Christopher B. Morrow, Gregory M. Pontone, Abhimanyu Mahajan   +5 more
wiley   +1 more source

Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study

BMC Neurology
Background Pimavanserin is approved by the US Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson’s disease.
Yasar Torres-Yaghi, Lambros Chrones, Victor Abler, Greg Brunson   +3 more
doaj   +1 more source

Semantic memory is impaired in both dementia with Lewy Bodies (DLB) and dementia of Alzheimer's type (DAT): a comparative neuropsychological study and literature review [PDF]

, 2001
OBJECTIVE---To test the hypothesis that semantic impairment is present in both patients with dementia with Lewy bodies (DLB) and those with dementia of Alzheimer's type (DAT).
Garrard, P., Hodges, J.R., Howard, D., Lambon Ralph, M.A., Powell, J., Whitworth, A.B.   +5 more
core  

Analytical performance and clinical utility of the INNOTEST (R) PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies [PDF]

, 2006
Background: Total tau (T-tau) and beta-amyloid((1-42)) (A beta(1-42)) levels in cerebrospinal fluid (CSF) can differentiate Alzheimer's disease (AD) from normal aging or depressive pseudo-dementia.
Blennow, Blennow, Buerger, Buerger, Buée, Folstein, Goedert, Goedert, Hampel, Hulstaert, Jimenez, Lewczuk, Maddalena, McKeith, McKhann, Mollenhauer, Mollenhauer, Nägga, Olsson, Riemenschneider, Schoonenboom, Sjögren, Vandermeeren, Vanderstichele, Vanmechelen, Wiltfang   +25 more
core   +1 more source

Quantitative Analysis of Locus Coeruleus Neurons and Thalamic Noradrenergic Axons in a Progressive 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine Monkey Model of Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Parkinson's disease is mainly characterized by dopaminergic neurodegeneration in the substantia nigra pars compacta (SNc) and α‐synuclein accumulation. The locus coeruleus (LC) is also affected in Parkinson's disease and linked to some nonmotor symptoms, but the extent and timing of its degeneration remain unclear.
Megan Carrillo, Nagore Hernández‐Pinedo, Josefa Zaldivar‐Diez, Isabel Pérez‐Santos, José A. Obeso, Carmen Cavada, Javier Blesa   +6 more
wiley   +1 more source